Clinical data
Trade names Plenaxis
AHFS/Drugs.com Monograph
  • US: X (Contraindicated)
Routes of
Intramuscular injection
ATC code L02BX01 (WHO)
Pharmacokinetic data
Protein binding 96–99%
CAS Number 183552-38-7 N
PubChem (CID) 16131215
DrugBank DB00106 YesY
ChemSpider 10482301 YesY
UNII W486SJ5824 YesY
KEGG D02738 YesY
ChEBI CHEBI:337298 YesY
Chemical and physical data
Formula C72H95ClN14O14
Molar mass 1416.06 g/mol
3D model (Jmol) Interactive image
 NYesY (what is this?)  (verify)

Abarelix (trade name Plenaxis) is an injectable gonadotropin-releasing hormone antagonist (GnRH antagonist). It is primarily used in oncology to reduce the amount of testosterone made in patients with advanced symptomatic prostate cancer for which no other treatment options are available.[1][2]

It was originally marketed by Praecis Pharmaceuticals as Plenaxis,[1] and is now marketed by Speciality European Pharma in Germany[3] after receiving a marketing authorisation in 2005. The drug was introduced in the United States in 2003, but was discontinued in this country in May 2005 due to poor sales and a higher-than-expected incidence of severe allergic reactions.[4]


  1. 1 2 Drugs.com: Abarelix
  2. Boccon-Gibod, L.; Van Der Meulen, E.; Persson, B. -E. (2011). "An update on the use of gonadotropin-releasing hormone antagonists in prostate cancer". Therapeutic Advances in Urology. 3 (3): 127–140. doi:10.1177/1756287211414457. PMC 3159401Freely accessible. PMID 21904569.
  3. Pharmazeutische Zeitung online: Abarelix (German)
  4. Boris Minev (13 January 2011). Cancer Management in Man: Chemotherapy, Biological Therapy, Hyperthermia and Supporting Measures. Springer Science & Business Media. pp. 182–. ISBN 978-90-481-9704-0.

This article is issued from Wikipedia - version of the 11/22/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.